Weiss Ratings reiterated their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT - Free Report) in a report released on Saturday,Weiss Ratings reports.
2seventy bio Stock Performance
NASDAQ:TSVT traded down $0.28 on Friday, reaching $2.30. The company's stock had a trading volume of 528,485 shares, compared to its average volume of 308,251. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $6.40. The business's 50-day moving average price is $2.95 and its two-hundred day moving average price is $3.99. The firm has a market cap of $118.66 million, a PE ratio of -1.24 and a beta of 1.74.
Institutional Trading of 2seventy bio
Large investors have recently bought and sold shares of the business. Regeneron Pharmaceuticals Inc. bought a new stake in shares of 2seventy bio during the fourth quarter worth $3,689,000. Western Standard LLC acquired a new position in 2seventy bio in the 3rd quarter worth $1,350,000. BBR Partners LLC increased its holdings in 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company's stock worth $850,000 after purchasing an additional 155,000 shares in the last quarter. PDT Partners LLC acquired a new stake in shares of 2seventy bio in the 3rd quarter valued at about $244,000. Finally, FMR LLC lifted its holdings in shares of 2seventy bio by 22.0% in the third quarter. FMR LLC now owns 148,545 shares of the company's stock valued at $701,000 after purchasing an additional 26,738 shares in the last quarter. 93.90% of the stock is owned by institutional investors.
2seventy bio Company Profile
(
Get Free Report)
2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.
Featured Stories
Before you consider 2seventy bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 2seventy bio wasn't on the list.
While 2seventy bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
